Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment



Status:Active, not recruiting
Conditions:Lymphoma, Orthopedic, Hematology
Therapuetic Areas:Hematology, Oncology, Orthopedics / Podiatry
Healthy:No
Age Range:18 - Any
Updated:3/30/2019
Start Date:October 2011
End Date:October 2050

Use our guide to learn which trials are right for you!

Outcomes of Cutaneous T-Cell Lymphoma and Chronic Graft-Versus-Host Disease in Patients Treated With Extracorporeal Photopheresis

Extracorporeal Photopheresis (ECP) is a form of apheresis and photodynamic therapy in which
the peripheral blood is treated with 8-methoxypsoralen, which is then activated with UV
light. ECP is currently a standard therapy for cutaneous T-cell lymphoma (CTCL) and is also
effective for graft-versus-host disease (GVHD). The investigators would like to study the
outcomes (response rates) of patients receiving ECP treatment and other factors relating to
their disease and treatment, as well as procedural events, such as complications.

The investigators intend to report outcomes from the inception of this procedure at
Dartmouth-Hitchcock Medical Center (DHMC) in May 2008 through 9/30/11. Additionally, the
investigators would like to maintain a prospective database of these patients so that new
patient data can be collected for updating of outcomes.

Inclusion Criteria:

- Patients who receive Extracorporeal Photopheresis treatment

- Treated at Dartmouth-Hitchcock Medical Center

- Must be 18 years or older

Exclusion Criteria:

- None specified
We found this trial at
1
site
1 Medical Center Dr
Lebanon, New Hampshire 03756
 (603) 650-5000
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
?
mi
from
Lebanon, NH
Click here to add this to my saved trials